Leave cancer nowhere to hide </span><span> 

Leave cancer nowhere to hide  

Imaging and microscopy webinar series

Join our webinars and learn about the ground-breaking imaging and microscopy technologies that can help you boost your cancer and immuno-oncology research.

Cutting-edge imaging and microscopy technologies open new avenues for cancer and immuno-oncology research – from ultrahigh-content imaging, which smashes the boundaries of traditional multiplexed techniques, to large-scale light sheet microscopy, which enables 3D imaging of entire organs or tumor tissue on a subcellular level.  

Don’t engage in a game of hide and seek with cancer and immune cells. Study the tumor immune microenvironment in unprecedented detail by analyzing hundreds of markers on a single sample. Detect single disseminated cancer cells in an entire human organ, identify new CAR target candidates, or track CAR T cells in solid tumors. Learn how in this online seminar series. 

Program overview

Session 1: Ultrahigh-content imaging: a breath of fresh air for lung cancer research 

Session 2: Studying solid tumors and their microenvironment based on automated large-scale 3D fluorescence imaging

Session 3: Overcoming challenges in preclinical target discovery and validation

Session 4: Ultrahigh-content imaging helps to identify CAR target candidates against pancreatic adenocarcinoma

Session 1: Ultrahigh-content imaging: a breath of fresh air for lung cancer research 

Tuesday, March 9, 2021
Berlin, Germany (GMT+01:00)  − 5:00 p.m. CET
San Francisco, CA, USA (GMT-08:00) − 8:00 a.m. PST
New York, NY, USA (GMT-05:00)  − 11:00 a.m. EST
 
Presenter: Dr. Telma Santos

Webinar abstract

MICS (MACSima™ Imaging Cyclic Staining) technology allows imaging of hundreds of markers on a single sample and processing of multiple samples in a single experiment. See how more than 150 antibodies were used to investigate two of the most common non-small-cell lung cancers (lung adenocarcinoma and squamous-cell carcinoma) with special focus on the infiltration of immune cells into the tumor tissue.   

The possibility of analyzing hundreds of markers on one sample not only facilitates the identification of basic structures, but it also enables the analysis of a plethora of proteins to advance biomarker research, drug target discovery, and deep phenotyping. Ultimately, all these approaches can help advance research towards the development of novel diagnostics and therapies. 

Session 2: Studying solid tumors and their microenvironment based on automated large-scale 3D fluorescence imaging

Thursday, March 25,  2021
Berlin, Germany (GMT+01:00)  − 4:00 p.m. CET
San Francisco, CA, USA (GMT-07:00) − 8:00 a.m. PST
New York, NY, USA (GMT-04:00)  − 11:00 a.m. EST
 
Presenters: Dr. Nizar Yousif and Dr. Hussein Hamzeh 

Webinar abstract

Profound analysis of the heterogeneous tumor physiology and cellular dynamics within the tumor microenvironment requires comprehensive 3D imaging data. Commonly used techniques of classic histology and 2D microscopy are unable to meet this need. The new UltraMicroscope Blaze™ Light Sheet Imaging System eliminates this shortcoming as it enables high-resolution 3D visualization of large solid tumors and their microenvironment. This platform allows quantification of multiple tumor parameters and cell infiltration into the tumor (e.g. CAR T cell tracking) at subcellular resolution. The resultant 3D data from entire solid tumors support early drug development by providing new insights into drug delivery pathways, for example. Multiple smaller samples like spheroids can be imaged automatically in one run to reduce hands-on time.  

Session 3: Overcoming challenges in preclinical target discovery and validation

Thursday, April 15,  2021
Berlin, Germany (GMT+02:00)  −  1:10 p.m. CET
San Francisco, CA, USA (GMT-07:00) − 4:10 a.m. PST
New York, NY, USA (GMT-04:00)  − 7:10 a.m. EST
 
Presenter: Dr. Olaf Hardt

Roundtable discussion topic

Target discovery and validation remain a major roadblock slowing down the development of efficient immunotherapies for the fight against cancer. Take the chance and discuss challenges and new ways to overcome these hurdles with Dr. Olaf Hardt, Senior Manager in the R&D department of Miltenyi Biotec.

Session 4: Ultrahigh-content imaging helps to identify CAR target candidates against pancreatic adenocarcinoma 

Tuesday, April 20,  2021
Berlin, Germany (GMT+02:00)  − 5:00 p.m. CET
San Francisco, CA, USA (GMT-07:00) − 8:00 a.m. PST
New York, NY, USA (GMT-04:00)  − 11:00 a.m. EST
 
Presenter: Dr. Daniel Schäfer  

Webinar abstract

Making use of the innovative MICS (MACSima Imaging Cyclic Staining) technology, Daniel Schäfer has overcome a major scientific obstacle which so far has impeded the development of effective cellular immunotherapy of pancreatic ductal adenocarcinoma – the lack of suitable tumor-specific antigens. His research led to the identification of four target candidates among 371 antigens. This in turn resulted in the generation of 32 CARs whose potential for therapeutic approaches has been evaluated. Daniel Schäfer will explain how he identified the potential targets, how CAR T cell activity was evaluated in vitro and, based on that, how promising constructs were used to assess their activity in vivo. Efficacies in pre-clinical studies ranged from stabilized disease to complete tumor eradication.